Jefferies has reiterated a Buy rating on Global Health Ltd. (Medanta) with a target price of ₹1,170, implying an upside of 6.4% from the current market price (CMP) of ₹1,099.25.
The brokerage remains optimistic about the company’s steady operations at its flagship Gurugram facility and highlights a sequential recovery in its Lucknow and Patna hospitals. Strong operational metrics continue to drive growth across key locations.
Looking ahead, Global Health has earmarked ₹2,800 crore in capital expenditure over the next five years to add nearly 2,900 beds. While the delay at the Indore project is a disappointment, the company is actively exploring alternative options to enter the market.
The stock gained 2.24% yesterday, closing at ₹1,099.25. Investors will likely monitor the progress of expansion projects and any updates on the Indore development closely.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a financial advisor before making any investment decisions.